Endocrine Abstracts

Aims: Both functional hypogonadism (FH) and type 2 diabetes (T2D) negatively affect bone mineral density (BMD). We aimed to evaluate changes on bone turnover markers (BTMs) and BMD in obese males with FH and T2D due to testosterone therapy (TTh).Research Design and Methods: 55 obese males with FH and T2D participated in a two-year (first year double-blind, placebo-controlled study, second year follow-up) clinical trial. Participants were randomized into ...

Aims: Testosterone therapy (TTh) has been postulated to increase the risk of prostate adverse events (PAEs) and erythrocytosis, risk further exacerbated in high-risk obese patients with type 2 diabetes (T2D) and functional hypogonadism (FH). We investigated safety aspects of TTh in obese males with FH and T2D by observing the incidence of PAEs and erythrocytosis and determining when statistically significant difference from the baseline manifests in hematocrit (Hct) and prosta...

Functional hypogonadism and prevalence of decreased total testosterone level in type 2 diabetic male patientsBackground: Approximately 50 % of older males with obesity and type 2 diabetes, exhibit low total testosterone levels, many also signs of hypogonadism. Functional hypogonadism negatively affects glycemic control, exacerbates early cardio-vascular complications, causes lower bone mineral density, erectile dysfunction, reduces lean body mass, and ac...

Background: The association between testosterone deficiency, metabolic syndrome (MetS) and type 2 diabetes (T2DM) is well established. Male hypogonadism is related to an increase in glycometabolic and cardiometabolic complications.Objective: To evaluate magnitude of effects of testosterone replacement therapy (TRT) on testosterone normalization, parameters of the MetS and vascular function and morphology in obese hypogonadal male patients with T2DM.<...